I think the management ran the public listed company poorly. If it ran as a private company, it may be OK but the demands for timelines by the sharemarket seem to be too challenging and distracting for this company. I guess the only strategy the company have left is a takeover target once the FDA approval is obtained.
I don't write this off but I'm not holding out any hope for any short term price movements at all.
